{
    "organizations": [],
    "uuid": "e544fe9c9a255046b17aad96ff593c2ef19c8c92",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vertex-initiates-late-stage-study/brief-vertex-initiates-late-stage-study-of-treatment-combination-for-cystic-fibrosis-idUSASM000JKL",
    "ord_in_thread": 0,
    "title": "BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS\n* VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION\n* VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-22T05:12:00.000+02:00",
    "crawled": "2018-02-22T17:57:01.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "initiate",
        "first",
        "phase",
        "study",
        "tezacaftor",
        "ivacaftor",
        "triple",
        "combination",
        "regimen",
        "people",
        "cystic",
        "fibrosis",
        "vertex",
        "pharmaceutical",
        "inc",
        "global",
        "phase",
        "study",
        "enroll",
        "patient",
        "one",
        "f508del",
        "mutation",
        "one",
        "minimal",
        "function",
        "mutation",
        "vertex",
        "phase",
        "study",
        "designed",
        "support",
        "submission",
        "nda",
        "based",
        "primary",
        "efficacy",
        "endpoint",
        "safety",
        "data",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}